Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925859 | 0.85 | — | — | |
| SCHEMBL25925841 | 0.79 | MEN1 (0.34) | MEN1MAPTHTTKMT2ATDP1 | |
| SCHEMBL25925849 | 0.78 | MAPT (0.34) | MEN1MAPTHTTKMT2ATDP1 | |
| SCHEMBL25925847 | 0.77 | MEN1 (0.32) | MEN1MAPTHTTKMT2ATDP1 | |
| SCHEMBL25925839 | 0.76 | — | — | |
| SCHEMBL25927695 | 0.75 | MEN1 (0.32) | MEN1MAPTHTTKMT2ATDP1 | |
| SCHEMBL25925843 | 0.75 | MEN1 (0.31) | MEN1MAPTHTTKMT2ATDP1 | |
| SCHEMBL25927687 | 0.74 | MEN1 (0.31) | MEN1MAPTHTTKMT2ATDP1 | |
| SCHEMBL25927794 | 0.74 | GLO1 (0.32) | — | |
| SCHEMBL25925858 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | AR, MAPT, NR5A1 | MEN1 67/4885MAPT 2/4885HTT 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.